The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi)
Publications
Dabrafenib/Trametinib Combination Approved in BRAF-Mutant Melanoma
The US Food and Drug Administration (FDA) granted approval to the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for the adjuvant treatment of melanoma.
Melbourne Melanoma Project / Melanoma Research Victoria Newsletter – Issue 9, May 2018
Please follow this link to download the 9th edition of the MMP/MRV newsletter. Melbourne Melanoma Project Newsletter – Issue 9, May 2018
Read More Once Monthly Opdivo Use Approved in EU for Certain Melanoma, Renal Cell Cancer Patients
The European Commission has approved a new dosing schedule for Opdivo(nivolumab), allowing the PD-1 inhibitor to be given every four weeks to patients with advanced melanoma and those with previously treated renal cell carcinoma.